The Cactus Life Sciences team contributes to the publishing industry’s understanding of medical communications by conducting research and putting forth opinion on key industry challenges and areas of interest.
These research works and opinion pieces may be presented as posters at industry conferences or published in relevant industry journals. The following are two journal publications authored by members of our team
- Res Integr Peer Rev. 2019 Oct 2;4:21. doi: 10.1186/s41073–019–0079–1. eCollection 2019.
A guide to applying the Good Publication Practice 3 guidelines in the Asia-Pacific region
This commentary focuses on how well industry standards like the Good Publication Practice 3 (GPP3) guidelines and the International Committee of Medical Journal Editors (ICMJE) criteria for authorship are understood and applied in the Asia Pacific region. The authors discuss potential barriers to compliance with these guidelines and make suggestions for better uptake and compliance.
2. JAMA Intern Med. 2015 Sep;175(9):1587. doi: 10.1001/jamainternmed.2015.3229.
A Potential Solution for Research Misconduct
In this Letter to the Editor, the authors respond to a previously published article on research misconduct identified by the US FDA, proposing that there be a regulatory requirement that all forms of clinical trial data communications—from the clinicaltrials.gov database through all presentations and publications (including
the product-prescribing information document [PID])—should contain clinicaltrials.gov identifiers.
About the author
Cactus Life Sciences
Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.